Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2022

Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: A Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Trial

Ann Rheum Dis. 2022 2022 2022-222849

Ayaz NA,

Ozen S,

Scott C,

Zhu X,

Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

In the latest study by Brunner, et al. secukinumab demonstrated efficacy and safety in the JIA categories of ERA and JPsA. This phase 3 study aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA.

Keywords:

February 2022

Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis

Clin Rheumatol. 2022. Epub ahead of print doi: 10.1007/s10067-021-06003-z

Li N,

Gou ZP,

Du SQ,

Zhu XH,

Lin H,

Liang XF,

Wang YS,

Feng P.

Systematic review and network meta-analysis highlight that RA patients who receive recommended doses of the five approved JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib, and peficitinib) are likely to experience an increase in serum low- and high-density lipoprotein (LDL and HDL) levels.JAK inhibitors have been associated with alterations in levels of LDL and HDL cholesterol, which may lead to dyslipidaemia (an important risk factor for cardiovascular disease). However, the e...